Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05852223
Title Pembrolizumab in High-risk Thyroid Cancer (NePenThe)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Istituti Clinici Scientifici Maugeri SpA
Age Groups: adult | senior
Covered Countries ITA

Facility Status City State Zip Country Details
Istituti Clinici Scientifici Maugeri Pavia Lombardia 27100 Italy Details
*Shaded cells indicate that there was no data available from for the field